aspirin versus clopidogrel

Phase 1Small molecule

aspirin versus clopidogrel is one of 15 small molecule programs targeting Transient Ischemic Attack. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Transient Ischemic AttackActive, not recruiting

Transient Ischemic AttackPhase 1

Active, not recruiting

Competition

Competitive Landscape

17 competitors in Transient Ischemic Attack

#DrugCompanyPhaseTrials

Prevacid

Takeda

Approved

—2

Colcrys

Alnylam Pharmaceuticals

Phase 3

1 3

Zocor

OOrganon and Co

Phase 3

1 4

Plavix

Sanofi

Phase 2

3 5

Bayer Aspirin

Bayer

Phase 2

2 6

Antihypertensive Medication

UUniversity of Alberta

Approved

1 7

Simdax

Orion Corporation, Orion Pharma

Milvexian

Pradaxa

1 10

Acetylsalicylic Acid

Bayer

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Transient Ischemic Attack1 trial

Pilot Study of Continuing Aspirin Versus Switching to Clopidogrel After Stroke or Transient Ischemic Attack

Withdrawn·UUniversity of California, San Diego·Phase 1·NCT00363753

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for aspirin versus clopidogrel. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — aspirin versus clopidogrel compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for aspirin versus clopidogrel. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of California, San Diego company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: UUniversity of California, San Diego

aspirin versus clopidogrel

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Transient Ischemic Attack1 trial

References

Drug Info

Quick Facts

Related News